Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
p21-activated kinase 4 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
p21-activated kinase 4 (PAK4) siRNA is a small interfering RNA designed to silence the expression of the PAK4 gene through the RNA interference (RNAi) pathway. PAK4 is a member of the Group II p21-activated kinases and serves as a critical downstream effector for Rho family GTPases, such as Cdc42 and Rac. It is involved in various cellular processes including cytoskeletal remodeling, cell survival, and proliferation. In many human cancers, PAK4 is overexpressed and contributes to tumor progression, epithelial-mesenchymal transition (EMT), and resistance to apoptosis or radiation. As a research reagent, PAK4 siRNA is used in preclinical models to investigate the biological consequences of PAK4 knockdown, demonstrating potential in inhibiting tumor growth and migration in malignancies such as glioblastoma, pancreatic cancer, and gastric cancer.
- Other names
- p21-activated kinase 4 small interfering RNAp-21-activated kinase 4 small interfering RNAp 21-activated kinase 4 small interfering RNAsiRNA-mediated PAK4 downregulation
02
Targets
PAK4
Beyond the preview
Go deeper on p21-activated kinase 4 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on p21-activated kinase 4 siRNA.